Featured Research

from universities, journals, and other organizations

Chemical strategy hints at better drugs for osteoporosis, diabetes

Date:
June 16, 2014
Source:
University of Wisconsin-Madison
Summary:
By swapping replacement parts into the backbone of a synthetic hormone, researchers have built a version of a parathyroid hormone that resists degradation in laboratory mice. As a result, the altered hormone can stay around longer — and at much higher concentration, says the lead researcher.

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice. As a result, the altered hormone can stay around longer -- and at much higher concentration, says Gellman, professor of chemistry at the UW.

Hormones are signaling molecules that are distributed throughout the body, usually in the blood. Hormones elicit responses from only those cells that carry appropriate receptor molecules. "Receptors have evolved to recognize a very specific signal in a sea of biological fluids that is full of molecular messages," Gellman says.

The relationship between a receptor and its signaling molecule is often likened to that between a lock and a key.

"We're excited because we have preserved the ability to activate the receptor" by altering the backbone of the hormone, which holds the essential contact points in place, Gellman says. "While retaining, even enhancing, the signaling ability, we have diminished the peptide's susceptibility to the biodegradation mechanisms that nature uses to eliminate signals over time."

Peptides are segments of proteins. Peptide hormones, like the better-known steroid hormones such as estrogen and testosterone, can convey a signal to billions of cells at once, even at tiny concentrations.

For a study published June 15 in Nature Biotechnology, the researchers altered a highly successful synthetic parathyroid hormone called teriparatide, which is used to combat severe osteoporosis.

But the real excitement of the discovery is the potential impact on a large class of peptide drugs, Gellman says. "A substantial group of receptors, including some involved in diabetes, respond to peptide signals, but peptides are quickly degraded in the body. Our approach seems to suggest a general strategy to retain the ability to target a specific receptor while diminishing the action of degrading enzymes. The key is that the receptor is looking for one shape while the destructive enzyme seeks a different shape."

Gellman says the idea of replacing segments of the peptide backbone with artificial units once seemed heretical. "Most people expected that you could not change the backbone, which alters the spacing and orientation of the essential contact points, without making the molecule unrecognizable to the receptor."

Gellman has assigned his rights for the discovery to the Wisconsin Alumni Research Foundation. The study's first author, Cheloha, is a Ph.D. candidate in chemistry at UW-Madison. Co-author Thomas J. Gardella led a team at Harvard Medical School that conducted the biological assessments.

Potentially, the "alter-the-backbone" strategy could allow oral dosing of the rather fragile peptide drugs, which today must be injected to avoid destruction in the stomach and small intestine. By protecting the drugs from degrading enzymes, the new approach could also help sustain higher drug concentrations in the bloodstream.

The altered backbone also seems to make minor changes in signals that the receptor, once activated, transmits into the cell, Gellman says. "Changing the sites of backbone modification results in different profiles of response. Building drug molecules that activate only a certain type of response might allow us to dial out undesired side effects; but that's just a hope at this point."

To date, much of the focus on drug development has concerned the external features of signaling molecules, which directly contact a receptor, Gellman says. "The traditional approach is to keep the skeleton the same and modify the surface components. Our approach is just the opposite, keep the surface components the same, and modify the skeleton. Now that it is clear that this non-traditional approach can be successful, others are likely to try it."


Story Source:

The above story is based on materials provided by University of Wisconsin-Madison. The original article was written by David Tenenbaum. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ross W Cheloha, Akira Maeda, Thomas Dean, Thomas J Gardella, Samuel H Gellman. Backbone modification of a polypeptide drug alters duration of action in vivo. Nature Biotechnology, 2014; DOI: 10.1038/nbt.2920

Cite This Page:

University of Wisconsin-Madison. "Chemical strategy hints at better drugs for osteoporosis, diabetes." ScienceDaily. ScienceDaily, 16 June 2014. <www.sciencedaily.com/releases/2014/06/140616203951.htm>.
University of Wisconsin-Madison. (2014, June 16). Chemical strategy hints at better drugs for osteoporosis, diabetes. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/06/140616203951.htm
University of Wisconsin-Madison. "Chemical strategy hints at better drugs for osteoporosis, diabetes." ScienceDaily. www.sciencedaily.com/releases/2014/06/140616203951.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins